Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA survey

This article was originally published in The Tan Sheet

Executive Summary

Telephone, mail, shopping mall intercept and Internet surveys to gauge consumers' understanding of conventional food, dietary supplement labeling could begin in six weeks, FDA says in a 1Feb. 21 Federal Register notice. Agency requests "emergency processing" of proposed survey from OMB, since "the information is critical to [FDA's] mission of regulating food labeling." Survey will include 7,000 respondents' evaluations of various label statements. Agency will accept comments until March 25; OMB processing should take two weeks. FDA also awaits OMB approval of Health & Diet Survey to evaluate consumer knowledge, beliefs about supplements (2"The Tan Sheet" Aug. 13, 2001, p. 11)...

You may also be interested in...



FDA labeling study

Survey to gauge consumers' understanding of food, dietary supplement labeling approved by OMB, according to July 8 Federal Register notice. Survey includes 7,000 respondents, split between mail questionnaires (1,000), telephone surveys (2,000) and Internet or cable surveys (4,000), FDA says. Total estimated burden is 4,000 hours. Agency requested emergency OMB approval for survey in February, citing it as "critical" to FDA's mission of regulating food labeling (1"The Tan Sheet" Feb. 24, 2002, In Brief). Agency also is conducting Health & Diet Survey, designed to evaluate consumers' knowledge and practices regarding supplements (2"The Tan Sheet" Aug. 13, 2001, p. 11)...

FDA Supplement Survey Will Gauge Prevalence And Purpose Of Product Use

FDA's pending telephone survey of consumers' knowledge, beliefs and practices regarding dietary supplements will involve a nationally representative sample of 2,000 randomly selected adults.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Topics

UsernamePublicRestriction

Register

PS093661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel